Journal of immunology research and therapy最新文献

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer. 舒尼替尼和索拉非尼调节肝细胞癌的抗肿瘤免疫。

Journal of immunology research and therapy Pub Date : 2018-01-01 Epub Date: 2018-06-08

Dai Liu, Xiaoqiang Qi, Yariswamy Manjunath, Eric T Kimchi, Lixin Ma, Jussuf T Kaifi, Kevin F Staveley-O'Carroll, Guangfu Li

{"title":"Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer.","authors":"Dai Liu, Xiaoqiang Qi, Yariswamy Manjunath, Eric T Kimchi, Lixin Ma, Jussuf T Kaifi, Kevin F Staveley-O'Carroll, Guangfu Li","doi":"","DOIUrl":"","url":null,"abstract":"Sorafenib and sunitinib are multiple tyrosine kinase inhibitors. Both of them have been approved by the US FDA in the treatment of patients with malignancies. In order to develop an effective and clinically useful chemoimmunotherapy modality against hepatocellular cancer (HCC), we investigate their tumoricidal and immune modulatory effect in the setting of HCC. In vitro experiments suggested that sunitinib and sorafenib both induced HCC cell apoptosis at an equivalent level, but stronger suppressive function to cell proliferation was detected in sorafenib. Correspondingly, treatment of tumor-bearing mice with sorafenib led to the suppression of tumor growth to a larger extent than sunitinib. Flow cytometry showed that treatment with sunitinib, not sorafenib, significantly reduced the frequency of regulatory T cells (Tregs) and myeloid-derived suppressive cells (MDSCs) in tumor-bearing mice; and allowed splenic lymphocytes to produce equivalent levels of IFN-γ and TNF-α in response to vaccination as that in wild type mice. This activation was not detected in control and sorafenib-treated tumor mice. In addition, treatment of tumor-bearing mice with sunitinib followed by adoptive transfer of tumor antigen-specific CD8+ T cells and immunization resulted in the additional suppression to tumor growth compared to sunitinib monotherapy. These results imply treatment with sunitinib, not sorafenib, is able to prevent tumor-induced immunotolerance and activate antitumorimmunity. Our data suggest that sunitinib may be a preferable chemotherapeutic agent to use in combination with immunotherapy for the treatment of HCC.","PeriodicalId":73788,"journal":{"name":"Journal of immunology research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36410778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IL-27 Receptor Signaling on T cells Augments GVHD Severity through Enhancing Th1 Responses. T细胞上的IL-27受体信号通过增强Th1反应来增加GVHD的严重性。

Journal of immunology research and therapy Pub Date : 2018-01-01 Epub Date: 2018-06-07

David Bastian, Yuejun Liu, Yongxia Wu, Steven Schutt, Hung D Nguyen, Anusara Daenthanasanmak, M Hanief Sofi, Mengmeng Zhang, Supinya Iamsuwat, Xue-Zhong Yu

{"title":"IL-27 Receptor Signaling on T cells Augments GVHD Severity through Enhancing Th1 Responses.","authors":"David Bastian, Yuejun Liu, Yongxia Wu, Steven Schutt, Hung D Nguyen, Anusara Daenthanasanmak, M Hanief Sofi, Mengmeng Zhang, Supinya Iamsuwat, Xue-Zhong Yu","doi":"","DOIUrl":"","url":null,"abstract":"IL-27 is a heterodimeric cytokine comprised of IL-27p28 and EBI3. As a relatively new member of the IL-12 family, the biological mechanisms associated with the role of IL-27 in the immune response are ambiguous, displaying both proinflammatory and suppressive functions that seem to be dependent on the disease model. A recent report demonstrates that pharmacological blockade of IL-27p28 alleviates graft-versus-host disease (GVHD) in mice. However, the specific role of the IL-27Rα/gp130 signaling complex that forms the IL-27 receptor (IL-27R) on T cells has not been well characterized in the context of allogeneic hematopoietic stem cell transplantation (allo-HCT). Here, we demonstrate that IL-27Rα expression on T cells exacerbates GVHD after allo-HCT, which was consistent across 3 different MHC- mismatched murine models of allo-HCT. Expression of IL-27Rα on T cells was required for acquisition of optimal Th1 effector function and subsequent inhibition of Th2 and T regulatory subsets after allo-HCT. Furthermore, administration of IL-27significantly increased mortality after allo-HCT; suggesting that the suppressive functions linked to IL-27 in T cell responses may be relatively modest in this model. Hence, IL-27Rα signaling on T cells promotes the development of GVHD.","PeriodicalId":73788,"journal":{"name":"Journal of immunology research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37087676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Vitamin A in Modulating Graft-versus-Host Disease. 维生素A在调节移植物抗宿主病中的作用

Journal of immunology research and therapy Pub Date : 2018-01-01 Epub Date: 2018-06-03

Jianwei Zheng, Brian Taylor, Xiao Chen

引用次数: 0

Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy. 嵌合抗原受体(CAR) T细胞及其疗效影响因素。

Journal of immunology research and therapy Pub Date : 2017-06-01

Victoria G Kravets, Yi Zhang, Hongxing Sun

引用次数: 0

Targeting Cytokines in GVHD Therapy. 靶向细胞因子治疗GVHD

Journal of immunology research and therapy Pub Date : 2017-01-01 Epub Date: 2017-06-28

Sandeep Kumar, Hemn Mohammadpour, Xuefang Cao

{"title":"Targeting Cytokines in GVHD Therapy.","authors":"Sandeep Kumar, Hemn Mohammadpour, Xuefang Cao","doi":"","DOIUrl":"","url":null,"abstract":"Transplantation of donor-derived allogeneic hematopoietic cells causes increased survival in patients suffering from various blood cancers and other hematologic and immunologic diseases. However, this health benefit is limited to certain patients. One major complication is graft-versus-host disease (GVHD) that occurs when donor-derived immune cells recognize host cells/tissues as foreign and perpetrate subsequent destruction. Cytokines are a major class of effector molecules that are involved in GVHD pathogenesis. Proinflammatory cytokines released by activated immune cells including T cells lead to the onset of GVHD. T cell depletion (TCD) is an effective approach for GVHD prevention. Several immune suppressive drugs are also used to treat GVHD. However, these prophylactic and treatment strategies often lead to an immune compromised state that increases the risk for infection and cancer relapse. Considering the adverse effects of TCD and overall immune suppression, more selective managements such as approaches targeting proinflammatory cytokines have emerged as a promising strategy to control GVHD. Therefore, this work is dedicated to review recent development in the studies of cytokines and their future implication in GVHD therapy.","PeriodicalId":73788,"journal":{"name":"Journal of immunology research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35423963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies. 人工抗原提呈细胞在基于T细胞的癌症免疫治疗中的基础。

Journal of immunology research and therapy Pub Date : 2017-01-01 Epub Date: 2017-06-26

Lillian R Neal, Stefanie R Bailey, Megan M Wyatt, Jacob S Bowers, Kinga Majchrzak, Michelle H Nelson, Carl Haupt, Chrystal M Paulos, Juan C Varela

引用次数: 0